- Home
- ELBM vs CGTX Comparison
ELBM vs CGTX Comparison
Compare ELBM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- CGTX
- Stock Information
- Founded
- ELBM 2011
- CGTX 2007
- Country
- ELBM Canada
- CGTX United States
- Employees
- ELBM N/A
- CGTX N/A
- Industry
- ELBM Industrial Machinery/Components
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- CGTX Health Care
- Exchange
- ELBM Nasdaq
- CGTX Nasdaq
- Market Cap
- ELBM 19.5M
- CGTX 20.5M
- IPO Year
- ELBM N/A
- CGTX 2021
- Fundamental
- Price
- ELBM $1.00
- CGTX $0.24
- Analyst Decision
- ELBM Strong Buy
- CGTX Strong Buy
- Analyst Count
- ELBM 1
- CGTX 5
- Target Price
- ELBM $2.40
- CGTX $5.63
- AVG Volume (30 Days)
- ELBM 39.3K
- CGTX 1.1M
- Earning Date
- ELBM 05-13-2025
- CGTX 05-07-2025
- Dividend Yield
- ELBM N/A
- CGTX N/A
- EPS Growth
- ELBM N/A
- CGTX N/A
- EPS
- ELBM N/A
- CGTX N/A
- Revenue
- ELBM N/A
- CGTX N/A
- Revenue This Year
- ELBM N/A
- CGTX N/A
- Revenue Next Year
- ELBM N/A
- CGTX N/A
- P/E Ratio
- ELBM N/A
- CGTX N/A
- Revenue Growth
- ELBM N/A
- CGTX N/A
- 52 Week Low
- ELBM $0.91
- CGTX $0.22
- 52 Week High
- ELBM $2.83
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- ELBM 40.24
- CGTX 28.50
- Support Level
- ELBM $0.99
- CGTX $0.22
- Resistance Level
- ELBM $1.09
- CGTX $0.34
- Average True Range (ATR)
- ELBM 0.05
- CGTX 0.03
- MACD
- ELBM 0.00
- CGTX -0.01
- Stochastic Oscillator
- ELBM 31.37
- CGTX 14.41
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.